Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Amortization of Deferred Charges: 2015-2024

Historic Amortization of Deferred Charges for Outlook Therapeutics (OTLK) over the last 10 years, with Sep 2024 value amounting to $2.7 million.

  • Outlook Therapeutics' Amortization of Deferred Charges fell 76.17% to $99,849 in Q2 2020 from the same period last year, while for Jun 2020 it was $654,702, marking a year-over-year decrease of 54.21%. This contributed to the annual value of $2.7 million for FY2024, which is 6.01% up from last year.
  • According to the latest figures from FY2024, Outlook Therapeutics' Amortization of Deferred Charges is $2.7 million, which was up 6.01% from $2.5 million recorded in FY2023.
  • Over the past 5 years, Outlook Therapeutics' Amortization of Deferred Charges peaked at $2.7 million during FY2024, and registered a low of $235,636 during FY2020.
  • Moreover, its 3-year median value for Amortization of Deferred Charges was $2.5 million (2023), whereas its average is $2.3 million.
  • As far as peak fluctuations go, Outlook Therapeutics' Amortization of Deferred Charges crashed by 82.07% in 2020, and later spiked by 279.35% in 2021.
  • Yearly analysis of 5 years shows Outlook Therapeutics' Amortization of Deferred Charges stood at $235,636 in 2020, then surged by 279.35% to $893,886 in 2021, then surged by 85.18% to $1.7 million in 2022, then skyrocketed by 52.83% to $2.5 million in 2023, then increased by 6.01% to $2.7 million in 2024.